Firmonertinib before and after surgery for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted therapy pill (firmonertinib) given before and after surgery for stage II–III lung adenocarcinoma that has an EGFR mutation. The goal is to see if this approach can shrink the tumor before surgery and reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with lung adenocarcinoma (a type of non-small cell lung cancer).
- Your cancer is at stage II or III (AJCC 9th edition) and your doctor has confirmed it can be completely removed by surgery.
- Your tumor tests positive for a specific EGFR gene mutation (exon 19 deletion or L858R mutation).
- You have not had any prior anti-cancer treatment for this lung cancer, and you have not had major surgery in the month before starting the study drug.
- You are able to take care of yourself and are not severely limited in daily activities (ECOG performance status 0–1).
- You agree to use effective contraception during the study and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if Firmonertinib, a targeted pill, can prevent lung cancer from returning after surgery in people with non-small cell lung cancer that has certain uncommon EGFR gene changes. If you have had complete tumor removal and have one of these specific mutations, this study may help you stay cancer-free longer.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
This trial tests whether a higher dose of the targeted pill firmonertinib (160 mg) can better control advanced lung cancer in people who have a specific EGFR mutation and whose disease remained stable after a lower dose for 8 weeks. The goal is to see if the higher dose improves outcomes.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This trial tests a combination of two targeted drugs (firmonertinib and bevacizumab) given before surgery for people with early-stage, EGFR-mutated lung cancer. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
Hear when a new EGFR Positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.